KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, University of California San Diego, Institut Gustave Roussy, Institut Curie, Washington University in St. Louis, Hadassah Medical Center, Vall d'Hebron Hospital Universitari, Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947592840